ESMO26: HUTCHMED and AstraZeneca share positive outlook on NSCLC trials

Data from the SAFFRON and SANOVO trials with the Orpathys/Tagrisso combination will soon be unveiled at ESMO 2026 in Madrid, Spain. Data from the SAFFRON and SANOVO trials with the Orpathys/Tagrisso combination will soon be unveiled at ESMO 2026 in Madrid, Spain. HUTCHMED’s 23 September curtain-raiser noted that both the SAFFRON and SANOVO trials hit their primary endpoints with the Orpathys/Tagrisso combination against chemotherapy, and Tagrisso plus placebo, respectively, with more data expected at the European Society for Medical Oncology 2026 meeting. Image credit: [New Africa]/Shutterstock Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth clinical…

Source: Clinical Trials Arena